Back to News

Indiana CTSI Partners with GVK Biosciences to Provide National Access to Biomarker Database

June 08, 2011

June 08, 2011 — In an agreement facilitated by the Indiana Economic Development Corporation (IEDC) during a February economic mission to India, the Indiana Clinical and Translational Sciences Institute (Indiana CTSI) has partnered with GVK Biosciences, Asia’s leading Contract Research Organization, to provide researchers across the United States access to GVK BIO’s Clinical Biomarker Database that will advance research on wide range of diseases. The Indiana CTSI Bioinformatics Core and Indiana Institute for Personalized Medicine will work together to manage the process by which researchers access this new resource.

The GVK Biosciences Clinical Biomarker Database known as (GOBIOM) is a comprehensive collection of all clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. The resource will be available nationwide to 55 medical centers and universities supported by the Clinical and Translational Sciences Award from the National Institutes of Health.

“The GOBIOM database is a powerful tool for clinicians and researchers looking to mine the most up to date and comprehensive information about any putative biomarker for personalized therapeutics,” said Anantha Shekhar, director of the Indiana CTSI. “The Indiana CTSI is very pleased to partner with GVK BIO and the Indiana Institute for Personalized Medicine to make this resource available to all clinical and translational researchers in the national consortium. I am also grateful to the Indiana Economic Development Corporation for facilitating the GVK BIO and CTSI partnership.”

“GVK BIO is pleased that the Indiana CTSI chose the GVK BIO Biomarker Database for its research efforts. Biomarker research is increasing at a rapid pace and the database is designed to help researchers keep pace with the latest data. We look forward to collaborating with the CTSI and further improving the product to address the needs of the researchers and reviewers,” said Sreeni Devidas, Ph.D., vice president for sales and marketing in informatics at GVK Biosciences.

“From research and development to commercialization, Indiana’s wealth of expertise in life sciences has improved the knowledge and quality of medicine for researchers and patients around the world. The partnership between GVK Biosciences and the Indiana CTSI sprung from initial meetings during our February economic mission to India and has quickly developed into a tangible partnership that could be the precursor for future global opportunities,” said Mitch Roob, secretary of commerce and chief executive officer of IEDC. GOBIOM contains information on 12,000 biomarkers comprising biochemical, genomic, imaging, metabolite, cellular and physiological markers with multiple data points covering experimental, analytical, clinical and statistical data with their qualifications under different medical interventions. The GOBIOM database contains the latest and updated information on all the biomarkers reported in various clinical and preclinical studies.

About Indiana CTSI
The Indiana Clinical and Translational Sciences Institute (Indiana CTSI)  is a statewide collaboration of Indiana University, Purdue University and the University of Notre Dame, as well as public and private partnerships, which facilitates the translation of scientific discoveries in the lab into new patient treatments in Indiana and beyond. Established in 2008 with a $25 million Clinical and Translational Science Award (CTSA) from National Institutions of Health, supplemented by nearly $60 million from the state, the three member universities, and public and private partners, the Indiana CTSI is a member of a national network of 55 CTSA-funded organizations across the United States. For more information, visit

About GVK Biosciences
GVK Biosciences Private Limited (GVK BIO) is Asia’s leading Discovery Research and Chemical Development organization. GVK BIO provides a broad spectrum of services, stand-alone and integrated, across the R&D value chain. Our services consist of Discovery Chemistry, Discovery Biology and Informatics; the development services include Contract Research, Clinical Pharmacology and Process R&D. GVK BIO’s diverse portfolio of more than 150 customers includes some of the world’s largest pharmaceutical, biotechnology, agro, life-sciences companies and leading academic institutions.